Compare NVGS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVGS | IOVA |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | 2008 |
| Metric | NVGS | IOVA |
|---|---|---|
| Price | $21.52 | $3.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $21.50 | $9.00 |
| AVG Volume (30 Days) | 313.5K | ★ 14.0M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.63 | $1.64 |
| 52 Week High | $21.65 | $5.63 |
| Indicator | NVGS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 41.44 |
| Support Level | $17.38 | $2.05 |
| Resistance Level | N/A | $4.33 |
| Average True Range (ATR) | 0.62 | 0.26 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 87.30 | 4.33 |
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.